Pursuant to regulation 30 (read with Part A of Schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations'), we ....
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Innova Captab Limited's Board approved audited consolidated financial results for Q4 and FY ended March 31, 2026. Consolidated total income grew 30.4% YoY to ₹16,374 million, while net profit rose 9.9% to ₹1,409 million. Standalone net profit for FY26 was ₹837 million. The company declared an interim dividend of ₹2 per share in January 2026. Auditors BSR & Co. LLP issued an unmodified (clean) opinion on both standalone and consolidated results. The Board also amended the Related Party Transaction policy in compliance with Companies Act 2013. The company operates in the pharmaceuticals segment (drugs and pharmaceutical products) with subsidiaries including Univentis Medicare and Sharon Bio-Medicine. New labour codes effective November 2025 impact was accounted for in the results.
Strong topline growth of 30% YoY is positive, but net profit growth of ~10% indicates margin compression. Clean audit opinion and dividend declaration are shareholder-friendly. The stock may see positive reaction given robust revenue growth despite profitability being more modest.